Autolus Therapeutics Ltd traded at $1.40 this Monday February 2nd, increasing $0.03 or 2.19 percent since the previous trading session. Looking back, over the last four weeks, Autolus Therapeutics Ltd gained 24.73 percent. Over the last 12 months, its price fell by 33.65 percent. Looking ahead, we forecast Autolus Therapeutics Ltd to be priced at 1.34 by the end of this quarter and at 1.26 in one year, according to Trading Economics global macro models projections and analysts expectations.
Autolus Therapeutics plc, incorporated on February 2, 2018, is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The Company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.